HK2 and acute myeloid leukemia: The impact on clinical outcome is also reported—AML patients who did not achieve remission when compared to, either, healthy controls, or remission patients, show increased levels in distinct glycolysis elements, such as HIF1a, hexokinase 2 (HK2), glucose transporter 1 (GLUT1), and lactate dehydrogenase (LDH) [15].